{{Rsnum
|rsid=1800497
|Gene=ANKK1
|Chromosome=11
|position=113400106
|Orientation=minus
|ReferenceAllele=G
|MissenseAllele=A
|GMAF=0.2961
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=ANKK1
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 66.4 | 28.3 | 5.3
| HCB | 36.3 | 45.2 | 18.5
| JPT | 33.0 | 50.9 | 16.1
| YRI | 35.2 | 51.7 | 13.1
| ASW | 38.6 | 42.1 | 19.3
| CHB | 36.3 | 45.2 | 18.5
| CHD | 29.0 | 54.2 | 16.8
| GIH | 52.5 | 38.6 | 8.9
| LWK | 38.2 | 50.9 | 10.9
| MEX | 26.3 | 59.6 | 14.0
| MKK | 38.3 | 49.4 | 12.3
| TSI | 60.0 | 35.0 | 5.0
| HapMapRevision=28
}}[[rs1800497]], a SNP also known as the TaqIA (or Taq1A) polymorphism of the dopamine D2 receptor [[DRD2]] gene (even though it is actually located over 10,000bp downstream of the gene), gives rise to the DRD2*A1 allele. This allele ([[rs1800497]](T)) is associated with a reduced number of dopamine binding sites in the brain {{PMID|9672901}}, and has been postulated to play a role in [[alcoholism]], [[smoking]], and certain neuropsychiatric disorders.

The reduced number of dopamine binding sites may play a role in nicotine addiction by causing an "understimulated" state that can be relieved by smoking (and/or use of other drugs). {{PMID|8873216}}

A wide variety of reports have been published over more than ten years either linking [[rs1800497]] to aspects of nicotine use and smoking cessation success, or finding no such association. A meta-analysis of 41 such studies published in 2004 concluded that overall the association of [[rs1800497]] with such phenomena was statistically weak. {{PMID|15370155}} This same group recently (2009) published a study showing no association between rs1800497 and improved response to nicotine replacement therapy (NRT), contrary to their previous study.{{PMID|19273465}}

More recently, a relatively large study of over 700 patients attempting to kick their smoking habit using the drug [[bupropion]] determined that smokers homozygous for the A2/A2 genotype were more successful than A1/A2 or A1/A1 individuals. The A2/A2 smokers were more than three times as likely, relative to placebo, to be abstinent at end of treatment (35.2% vs. 15.1%; odds ratio = 3.25, CI: 2.00-5.28) and at 6 months of follow-up (26.7% vs. 12.2%; odds ratio = 2.81, CI: 1.66-4.77), whereas not so much by 12 months (16.3% vs. 10.7%; OR = 1.70, CI: 0.95-3.05). Basically, A1/A2 and A1/A1 genotype smokers didn't gain anything from using [[bupropion]] versus placebo; [[bupropion]] only helped A2/A2 genotypes stop smoking. {{PMID|18058343|OA=1
}}

In a study of individuals in the Polyp Prevention Trial with any, multiple (>/=2) or advanced colorectal adenoma recurrence after 4 years, compared to those without adenoma recurrence, [[rs1800497]](T;T) individuals were significantly associated with all advanced adenoma recurrence (odds ratio 2.40, CI: 1.11-5.20).  The authors speculate this increased risk of adenoma recurrence (and an association with [[colorectal cancer]]) may be related to SNP-associated differences in alcohol and fat intake.{{PMID| 19065655|OA=1
}}

A 2014 preliminary study links an individual's [[ANKK1]] [[rs1800497]] genotype as likely to experience greater positive subjective effects following cocaine exposure, including greater 'high' and 'like', and these individuals may have increased vulnerability to continue using cocaine or they may be at greater risk to relapse during periods of abstinence. The study states that replication of these findings is necessary to confirm these findings.{{PMID|24528631}}

SNPs [[rs6276]], [[rs6277]], and [[rs1800497]]) in the human [[DRD2]] gene are associated with decreased [[D2R]] expression and function, as well as [[high blood pressure]].  Data supports the hypothesis that [[D2R]] function has protective effects in human renal proximal tubule cells [[hRPTCs]] and suggest that carriers of these SNPs may be prone to [[chronic renal disease]] and [[high blood pressure]].  {{PMID|24379187}}

SNPs, [[rs1800497]] and [[rs2283265]], located near and within the dopamine receptor 2 [[DRD2]] gene, respectively, were significantly associated with improvements during working memory training (p < .003 and p < .0004, respectively). {{PMID|24001007}}

{{PMID|18698520|OA=1
}} A small (54 patient) study of patients with traumatic brain injury concluded that carriers of [[rs1800497]](A) alleles recover slower as assessed by memory and attention tests.

[http://blog.23andme.com/2008/10/16/genetics-may-dull-brains-pleasure-response-to-food-causing-weight-gain/ 23andMe blog] diminished pleasure response from food

{{ neighbor
| rsid = 2734849
| distance = 668
}}

{{PMID Auto
|PMID=19344737
|Title=Associations of the DRD2 TaqIA Polymorphism with Impulsivity and Substance Use: Preliminary Results from a Clinical Sample of Adolescents.
|OA=1
}}
{{PMID Auto
|PMID=19373123
|Title=Genetic variants altering dopamine D2 receptor expression or function modulate the risk of opiate addiction and the dosage requirements of methadone substitution
}}

{{omim
|id=608774
|desc=ANKYRIN REPEAT AND KINASE DOMAIN CONTAINING 1; ANKK1
|rsnum=1800497
}}
{{PMID Auto
|PMID=19796663
|Title=Influence of DRD2 and ANKK1 genotypes on apomorphine-induced growth hormone (GH) response in alcohol-dependent patients
}}

{{PMID Auto
|PMID=19925838
|Title=Parental Control and the Dopamine D2 Receptor Gene (DRD2) interaction on Emotional Eating in Adolescence
}}

[http://www.sciencemag.org/content/318/5856/1642.full#xref-ref-6-1 GENETICALLY DETERMINED DIFFERENCES IN LEARNING FROM ERRORS]

{{PharmGKB
|RSID=rs1800497
|Name_s=Taq1A (32806C>T)
|Gene_s=ANKK1
|Feature=
|Evidence=PubMed ID:1969501
|Annotation=Risk or phenotype-associated genotype: T. Phenotype: The A1 allele is associated with 24 (69%) of 35 alcoholics, but it associated with only 7 (20%) of 35 nonalcoholics. The absence of the A1 allele is associated with 28 (80%) of 35 nonalcoholics and with only 11 (31%) of 35 alcoholics. Study size: 35 alcoholics and 35 nonalcoholics. Study population: 46 whites; 24 blacks
|Drugs=ethanol
|Drug Classes=
|Diseases=Alcoholism
|Curation Level=Curated
|PharmGKB Accession ID=PA165291720
}}

{{PMID Auto
|PMID=19512960
|Title=Genetic diagnostics of functional variants of the human dopamine D2 receptor gene
}}

{{PMID Auto
|PMID=20350135
|Title=Prospective association of dopamine-related polymorphisms with smoking cessation in general care
}}

{{PharmGKB
|RSID=rs1800497
|Name_s=DRD2:Taq1A; DRD2:32806C>T
|Gene_s=ANKK1
|Feature=
|Evidence=Web Resource:http://www.pharmgkb.org/search/annotatedGene/drd2/variant.jsp
|Annotation=Associated with 12-month smoking cessation outcomes following treatment with a combination of bupropion and behavioral counseling in women.
|Drugs=bupropion
|Drug Classes=
|Diseases=
|Curation Level=In-Depth
|PharmGKB Accession ID=PA161145174
}}

{{PharmGKB
|RSID=rs1800497
|Name_s=DRD2 Taq1A
|Gene_s=ANKK1
|Feature=
|Evidence=PubMed ID:18058343
|Annotation=This variant (A2/A2 genotype) is associated with improved response to bupropion efficacy for smoking cessation.
|Drugs=bupropion
|Drug Classes=
|Diseases=Tobacco Use Disorder
|Curation Level=Curated
|PharmGKB Accession ID=PA162171873
}}

{{PharmGKB
|RSID=rs1800497
|Name_s=DRD2: TaqIA
|Gene_s=ANKK1
|Feature=
|Evidence=PubMed ID:18855532
|Annotation=This SNP is significant predictor of treatment response to risperidone in first-episode schizophrenia.
|Drugs=risperidone
|Drug Classes=
|Diseases=Schizophrenia
|Curation Level=Curated
|PharmGKB Accession ID=PA162356250
}}

{{PharmGKB
|RSID=rs1800497
|Name_s=DRD2:TaqIA allele
|Gene_s=ANKK1
|Feature=
|Evidence=PubMed ID:18927395
|Annotation=In blood oxygen level-dependent functional magnetic resonance imaging studies, obese college-aged women and adolescent girls showed a blunted striatal response to chocolate milkshake tasting (vs. tasting of a tasteless solution) when compared to lean women and girls, and the genotype at this SNP affected the extent of this response. This SNP is known as the TaqIA allele of DRD2 even though it is more than 10 KB downstream from the gene boundary.
|Drugs=
|Drug Classes=
|Diseases=Obesity
|Curation Level=Curated
|PharmGKB Accession ID=PA162370416
}}

{{PharmGKB
|RSID=rs1800497
|Name_s=DRD2:Taq1A A1
|Gene_s=ANKK1
|Feature=
|Evidence=PubMed ID:19339912
|Annotation=Risk or phenotype-associated allele: T. Phenotype: Carriers of one or two copies of the T allele of this variant (also known as Taq1A A1) were at higher risk of developing hyperprolactinemia than those with two copies of the C allele (also known as Taq1A A2). This variant is a SNP located about 9.5 kb downstream of the DRD2 coding region, and results in a Glu (C allele) to Lys (T allele) amino acid substitution in the ANKK1 protein. Study size: 90. Study population/ethnicity: 7-17-year-old patients chronically treated with risperidone; non-Hispanic Caucasians. Significance metric(s): OR = 3.1; p < 0.05. Type of association: CO.
|Drugs=risperidone
|Drug Classes=
|Diseases=Hyperprolactinemia
|Curation Level=Curated
|PharmGKB Accession ID=PA165108050
}}

{{PharmGKB
|RSID=rs1800497
|Name_s=Taq1A (32806C>T)
|Gene_s=ANKK1
|Feature=
|Evidence=PubMed ID:18086475
|Annotation=Risk or phenotype-associated genotype: T/T. Phenotype: Patients with one or two A1 alleles (T/T) had a greater risk of significant side effects, particularly if they were male. Study size: 116. Study population: Caucasians.
|Drugs=
|Drug Classes=ANTIPSYCHOTICS
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA165291714
}}

{{PharmGKB
|RSID=rs1800497
|Name_s=Taq1A (32806C>T)
|Gene_s=ANKK1
|Feature=
|Evidence=PubMed ID:17767146
|Annotation=Risk or phenotype-associated genotype: C/C. Phenotype: A meta-analysis showed that compared to tardive dyskinesia (TD)-negative patients, TD-positive patients had a higher A2 allele frequency (P = 0.003), with an effect-size of 1.30 (95% CI: 1.09-1.55), and higher A2/A2 genotype frequency (P = 0.001), with an effect-size of 1.50 (95% CI: 1.17-1.92). Study size: 1256 schizophrenia patients.
|Drugs=
|Drug Classes=ANTIPSYCHOTICS
|Diseases=tardive dyskinesia
|Curation Level=Curated
|PharmGKB Accession ID=PA165291715
}}

{{PharmGKB
|RSID=rs1800497
|Name_s=Taq1A (32806C>T)
|Gene_s=ANKK1
|Feature=
|Evidence=PubMed ID:19273465
|Annotation=Phenotype: This study found no association between the Taq1A polymorphism and response to nicotine replacement therapy.
|Drugs=
|Drug Classes=DRUGS USED IN NICOTINE DEPENDENCE
|Diseases=Tobacco Use Disorder
|Curation Level=Curated
|PharmGKB Accession ID=PA165291718
}}

{{PharmGKB
|RSID=rs1800497
|Name_s=Taq1A (32806C>T)
|Gene_s=ANKK1
|Feature=
|Evidence=PubMed ID:15492764
|Annotation=Risk or phenotype-associated genotype: T. Phenotype: Compared to women who carry both A2 (CC) alleles, women with at least one A1 (T) allele were more likely to report having stopped taking bupropion due to medication side effects (odds ratio (OR)=1.91, 95% confidence interval (CI)=1.01-3.60; P<0.04) and at 12 months were somewhat more likely to report smoking (OR=0.76, 95% CI=0.56-1.03; P<0.076). Significant associations or trends were not observed in men. Study size: 451 participants. Study population: Caucasian.
|Drugs=bupropion
|Drug Classes=
|Diseases=Tobacco Use Disorder
|Curation Level=Curated
|PharmGKB Accession ID=PA165291719
}}

{{PharmGKB
|RSID=rs1800497
|Name_s=Taq1A (32806C>T)
|Gene_s=ANKK1
|Feature=
|Evidence=PubMed ID:17989061
|Annotation=Risk or phenotype-associated genotype: T. Phenotype: This meta-analysis included 44 studies with 9,382 participants. For all studies combined, when we assumed the dominant model of gene action (A1A1 + A1A2 vs. A2A2), a small but significant association of alcohol dependency with being homozygote or heterozygote for the A1 allele was detected. The odds ratio was 1.38 (95 percent confidence interval (CI): 1.20, 1.58) when random effects were used. Study size: 5,273 cases and 3,995 controls.
|Drugs=ethanol
|Drug Classes=
|Diseases=Alcoholism
|Curation Level=Curated
|PharmGKB Accession ID=PA165291721
}}

{{PharmGKB
|RSID=rs1800497
|Name_s=TaqIA
|Gene_s=ANKK1
|Feature=
|Evidence=PubMed ID:18563706
|Annotation=Risk or phenotype-associated allele: T (A1). Phenotype: In a smoking cessation study the TaqIA SNP was significantly associated with being abstinent at 1 year (P = 0.01). Participants who carried at least one minor allele (A1) were less likely to quit compared to A2A2 homozygous (Odds Ratio: 0.47, 95% CI: 0.24-0.94). Study size: 881. metric(s): OR =0.47, 95% CI: 0.24-0.94.
|Drugs=
|Drug Classes=
|Diseases=Tobacco Use Disorder
|Curation Level=Curated
|PharmGKB Accession ID=PA165291618
}}

{{PharmGKB
|RSID=rs1800497
|Name_s=Taq1A (32806C>T)
|Gene_s=ANKK1
|Feature=
|Evidence=PubMed ID:15286066
|Annotation=Risk or phenotype-associated allele: T. Phenotype: In the combined medication group patients with the A1 (T) allele had 40% higher prolactin levels than patients without this allele. Study size: 144 schizophrenic patients. Study population: White patients.
|Drugs=clozapine; olanzapine; risperidone
|Drug Classes=ANTIPSYCHOTICS
|Diseases=Hyperprolactinemia
|Curation Level=Curated
|PharmGKB Accession ID=PA165291713
}}

{{PharmGKB
|RSID=rs1800497
|Name_s=Taq1A (32806C>T)
|Gene_s=ANKK1
|Feature=
|Evidence=PubMed ID:15077009
|Annotation=Risk associated genotype: C/C. Phenotype: In a randomized controlled trial investigating the short-term effectiveness of the nicotine patch, after 1 week of the trial the patch was more effective for smokers with CT/TT genotype (OR 2.80, 95% CI 1.70-4.61) than with CC (OR 1.41, 0.94-2.12; P for difference in ORs 0.04). Study size: 1532.
|Drugs=
|Drug Classes=DRUGS USED IN NICOTINE DEPENDENCE
|Diseases=Tobacco Use Disorder
|Curation Level=Curated
|PharmGKB Accession ID=PA165291717
}}

{{PharmGKB
|RSID=rs1800497
|Name_s=TaqIA (C/T)
|Gene_s=ANKK1
|Feature=
|Evidence=PubMed ID:20194480
|Annotation=Phenotype: A meta-analysis, including eight individual studies, was not able to detect an association between clinical response to antipsychotics and the Taq1A variant. Study size: meta-analysis included 8 individual studies, 748 patients total.
|Drugs=aripiprazole; Bromperidol; chlorpromazine; clozapine; haloperidol; nemonapride; risperidone
|Drug Classes=
|Diseases=Schizophrenia
|Curation Level=Curated
|PharmGKB Accession ID=PA165291679
}}

{{PharmGKB
|RSID=rs1800497
|Name_s=TaqIA
|Gene_s=ANKK1
|Feature=
|Evidence=PubMed ID:19603545
|Annotation=Phenotype: In this case-control study the polymorphisms -141C Ins/Del (rs1799732); C957T (rs6277); A1385G (rs6276); and TaqIA (rs1800497) were genotyped. The haplotypes I-C-G-A2 and I-C-A-A1 occurred with a higher frequency in alcoholics [P=0.026, odds ratio (OR): 1.340; P=0.010, OR: 1.521, respectively]. Study size: 360 alcoholics and 368 controls. Study population:Caucasian individuals of German origin.
|Drugs=ethanol
|Drug Classes=
|Diseases=Alcoholism
|Curation Level=Curated
|PharmGKB Accession ID=PA165291688
}}

{{PharmGKB
|RSID=rs1800497
|Name_s=TaqIA (C/T)
|Gene_s=ANKK1
|Feature=
|Evidence=PubMed ID:18926547
|Annotation=Phenotype: Compared with patients who had the A2/A2 (C/C) genotype, the positive and negative syndrome scale (PANSS) positive scores of A1/A1 (T/T) patients were 3.71 lower (p = 0.01) and of A1/A2 patients were 1.36 lower (p = 0.03) after 4-week aripiprazole treatment. These results suggest that A1 carriers are associated with superior therapeutic response on positive symptoms. Study size: 128 schizophrenic patients. Study population: Chinese.
|Drugs=aripiprazole
|Drug Classes=
|Diseases=Schizophrenia
|Curation Level=Curated
|PharmGKB Accession ID=PA165291677
}}

{{PharmGKB
|RSID=rs1800497
|Name_s=Taq1A (32806C>T)
|Gene_s=ANKK1
|Feature=
|Evidence=PubMed ID:10823405
|Annotation=Risk or phenotype-associated allele: T. Phenotype: In schizophrenic patients treated with nemonapride, the delta prolactin at 1 and 3 weeks was significantly (P<0.05) higher in female patients with the A1 allele than in males with or with no A1 allele. The delta prolactin at 3 weeks was also significantly (P<0.05) higher in the female patients with the A1 allele than in those with no A1 allele. Study size: 25 schizophrenic inpatients. Study population: Japanese.
|Drugs=nemonapride
|Drug Classes=
|Diseases=Hyperprolactinemia
|Curation Level=Curated
|PharmGKB Accession ID=PA165291712
}}

{{PharmGKB
|RSID=rs1800497
|Name_s=Taq1A (32806C>T)
|Gene_s=ANKK1
|Feature=
|Evidence=PubMed ID:18180754
|Annotation=Risk or phenotype-associated genotype: C/C. Phenotype: This meta-analysis suggests multiple genetic influences on tardive dyskinesia, including the Taq1A SNP. For Taq1A using the A1 allele as reference category, the study showed a risk-increasing effect for the A2 variant (OR=1.30, 95% CI: 1.03-1.65, P=0.026), and for A2-A2 homozygotes using A1-A1 as reference category (OR=1.80, 95% CI: 1.03-3.15, P=0.037).
|Drugs=
|Drug Classes=ANTIPSYCHOTICS
|Diseases=tardive dyskinesia
|Curation Level=Curated
|PharmGKB Accession ID=PA165291716
}}

{{PharmGKB
|RSID=rs1800497
|Name_s=TaqIA
|Gene_s=ANKK1
|Feature=
|Evidence=PubMed ID:20714340
|Annotation=Risk or phenotype-associated allele: T. Phenotype: The T allele was associated with weight gain of at least 7% in schizophrenia patients treatment with clozapine or olanzapine. Study size: 206. Study population/ethnicity: European american; German; Schizophrenia. Significance metric(s): OR = 2.18 (CI: 1.00-4.75). Type of association: PD.
|Drugs=clozapine; olanzapine
|Drug Classes=ANTIPSYCHOTICS
|Diseases=Weight gain
|Curation Level=Curated
|PharmGKB Accession ID=PA165374659
}}
{{PMID Auto
|PMID=21084795
|Title=Acute Intravenous Synaptamine Complex Variant KB220™ "Normalizes" Neurological Dysregulation in Patients During Protracted Abstinence From Alcohol and Opiates as Observed Using Quantitative Electroencephalographic and Genetic Analysis for Reward Polymorphisms: Part 1, Pilot Study with 2 Case Reports
}}
{{PMID Auto
|PMID=21244440
|Title=Risky Alcohol Use in Adolescence: The Role of Genetics (DRD2, SLC6A4) and Coping Motives
}}

{{omim
|id=608774
|rsnum=1800497
|variant=0001
}}

{{PMID Auto
|PMID=21456129
|Title=Single nucleotide polymorphism genotyping and point mutation detection by ligation on microarrays
}}

{{PMID Auto
|PMID=21540761
|Title=Association between DRD2/ANKK1 Taq1A genotypes, depression and smoking cessation with nicotine replacement therapy
}}

{{PMID Auto
|PMID=20505554
|Title=Association study between the DAT1, DBH and DRD2 genes and cocaine dependence in a Spanish sample
}}

{{PMID Auto
|PMID=21714067
|Title=Association between polymorphisms of DRD2 and DRD4 and opioid dependence: Evidence from the current studies
}}

{{PMID Auto
|PMID=22046326
|Title='Smoking Genes': A Genetic Association Study
|OA=1
}}

{{PMID Auto
|PMID=22438994
|Title=Dopaminergic Polymorphisms Associated with Time-on-Task Declines and Fatigue in the Psychomotor Vigilance Test
|OA=1
}}

{{PMID Auto
|PMID=22615781
|Title=Candidate Gene-Based Association Study of Antipsychotic-Induced Movement Disorders in Long-Stay Psychiatric Patients: A Prospective Study
|OA=1
}}

{{PMID Auto
|PMID=22541053
|Title=TaqIA polymorphism in dopamine D2 receptor gene complicates weight maintenance in younger obese patients.
}}

{{PMID Auto
|PMID=22579533
|Title=Binge eating disorder and the dopamine D2 receptor: Genotypes and sub-phenotypes.
}}

{{ClinVar
|rsid=1800497
|Reversed=1
|FwdREF=C
|FwdALT=T
|REF=G
|ALT=A
|RSPOS=113270828
|CHROM=11
|GMAF=0.2962
|dbSNPBuildID=89
|SSR=0
|SAO=1
|VP=0x05036800000017051f110101
|GENEINFO=ANKK1:255239
|GENE_NAME=ANKK1
|GENE_ID=255239
|WGT=0
|VC=SNV
|CLNALLE=1
|CLNHGVS=NC_000011.9:g.113270828G>A
|CLNORIGIN=1
|CLNSIG=5
|Tags=RV;PM;PMC;S3D;SLO;VLD;G5A;G5;HD;GNO;KGPhase1;KGPilot123;KGPROD;OTHERKG;PH3;LSD;OM
|CAF=0.7039; 0.2961
|CLNACC=RCV000002186.1; RCV000082708.1
|CLNDBN=Dopamine receptor d2, reduced brain density of; AllHighlyPenetrant
|CLNDSDB=MedGen
|CLNDSDBID=C1837439; CN169374
|CLNSRC=Emory University; OMIM Allelic Variant
|CLNSRCID=8524; 608774.0001
|COMMON=1
|Disease=Dopamine receptor d2; AllHighlyPenetrant
}}

{{PMID Auto
|PMID=15146457
|Title=Identification and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1.
}}

{{PMID Auto
|PMID=16380908
|Title=Preferential transmission of paternal alleles at risk genes in attention-deficit/hyperactivity disorder.
|OA=1
}}

{{PMID Auto
|PMID=17135598
|Title=No evidence for a major role of polymorphisms during bupropion treatment.
}}

{{PMID Auto
|PMID=17417059
|Title=A dopamine D2 receptor gene-related polymorphism is associated with schizophrenia in a Spanish population isolate.
}}

{{PMID Auto
|PMID=17466074
|Title=Genetic polymorphisms in dopamine-related genes and smoking cessation in women: a prospective cohort study.
|OA=1
}}

{{PMID Auto
|PMID=17483451
|Title=Gene-gene interaction associated with neural reward sensitivity.
|OA=1
}}

{{PMID Auto
|PMID=17585060
|Title=Genetic variants in the DRD2 gene moderate the relationship between stressful life events and depressive symptoms in adults: cardiovascular risk in young Finns study.
}}

{{PMID Auto
|PMID=17908762
|Title=Dopamine receptor D2 gene Taq1A (C32806T) polymorphism modifies the relationship between birth weight and educational attainment in adulthood: 21-year follow-up of the Cardiovascular Risk in Young Finns study.
}}

{{PMID Auto
|PMID=18077373
|Title=Polymorphisms in human dopamine D2 receptor gene affect gene expression, splicing, and neuronal activity during working memory.
|OA=1
}}

{{PMID Auto
|PMID=18154681
|Title=A lesson not learned: allele misassignment.
|OA=1
}}

{{PMID Auto
|PMID=18305461
|Title=Association between ADORA2A and DRD2 polymorphisms and caffeine-induced anxiety.
|OA=1
}}

{{PMID Auto
|PMID=18351593
|Title=DRD3, but not COMT or DRD2, genotype affects executive functions in healthy and first-episode psychosis adolescents.
}}

{{PMID Auto
|PMID=18354387
|Title=Significant association of ANKK1 and detection of a functional polymorphism with nicotine dependence in an African-American sample.
}}

{{PMID Auto
|PMID=18366720
|Title=Association of dopaminergic pathway gene polymorphisms with chronic renal insufficiency among Asian Indians with type-2 diabetes.
|OA=1
}}

{{PMID Auto
|PMID=18690117
|Title=Gene and gene by sex associations with initial sensitivity to nicotine in nonsmokers.
|OA=1
}}

{{PMID Auto
|PMID=18715757
|Title=Genetic associations with schizophrenia: meta-analyses of 12 candidate genes.
|OA=1
}}

{{PMID Auto
|PMID=18781856
|Title=Genetic underpinnings of tardive dyskinesia: passing the baton to pharmacogenetics.
}}

{{PMID Auto
|PMID=19238152
|Title=Interaction between dopamine D2 receptor genotype and parental rule-setting in adolescent alcohol use: evidence for a gene-parenting interaction.
}}

{{PMID Auto
|PMID=19258022
|Title=Now or Later? An fMRI study of the effects of endogenous opioid blockade on a decision-making network.
|OA=1
}}

{{PMID Auto
|PMID=19285111
|Title=C957T polymorphism of the human dopamine D2 receptor gene predicts extrastriatal dopamine receptor availability in vivo.
}}

{{PMID Auto
|PMID=19309284
|Title=Haplotype diversity and linkage disequilibrium at DRD2 locus--a study on four population groups of Andhra Pradesh, India.
}}

{{PMID Auto
|PMID=19321766
|Title=Dopamine DRD2 polymorphism alters reversal learning and associated neural activity.
|OA=1
}}

{{PMID Auto
|PMID=19470168
|Title=NPAS2 and PER2 are linked to risk factors of the metabolic syndrome.
|OA=1
}}

{{PMID Auto
|PMID=19526298
|Title=The ANKK1 kinase gene and psychiatric disorders.
}}

{{PMID Auto
|PMID=19664686
|Title=Potential association of DRD2 and DAT1 genetic variation with heroin dependence.
}}

{{PMID Auto
|PMID=19669131
|Title=Clinical and pharmacogenetic determinants for the discontinuation of non-ergoline dopamine agonists in Parkinson's disease.
|OA=1
}}

{{PMID Auto
|PMID=19693267
|Title=Financial and psychological risk attitudes associated with two single nucleotide polymorphisms in the nicotine receptor (CHRNA4) gene.
|OA=1
}}

{{PMID Auto
|PMID=19793394
|Title=Haplotype frequencies at the DRD2 locus in populations of the East European Plain.
|OA=1
}}

{{PMID Auto
|PMID=20138949
|Title=A genetic schizophrenia-susceptibility region located between the ANKK1 and DRD2 genes.
}}

{{PMID Auto
|PMID=20146828
|Title=Dopamine D2 receptor polymorphisms and susceptibility to alcohol dependence in Indian males: a preliminary study.
|OA=1
}}

{{PMID Auto
|PMID=20180986
|Title=CLOCK is suggested to associate with comorbid alcohol use and depressive disorders.
|OA=1
}}

{{PMID Auto
|PMID=20191112
|Title=The Genetics of Anorexia Nervosa: Current Findings and Future Perspectives.
|OA=1
}}

{{PMID Auto
|PMID=20199723
|Title=[DRD2/ANKK1 Taq IA polymorphism and early infant temperament].
}}

{{PMID Auto
|PMID=20205808
|Title=Association between dopaminergic polymorphisms and borderline personality traits among at-risk young adults and psychiatric inpatients.
|OA=1
}}

{{PMID Auto
|PMID=20446882
|Title=Do candidate genes discriminate patients with an autism spectrum disorder from those with attention deficit/hyperactivity disorder and is there an effect of lifetime substance use disorders?
}}

{{PMID Auto
|PMID=20452395
|Title=Association of functional variants in the dopamine D2-like receptors with risk for gambling behaviour in healthy Caucasian subjects.
}}

{{PMID Auto
|PMID=20567893
|Title=Association between polymorphisms of the dopamine receptor D2 and catechol-o-methyl transferase genes and cognitive function.
}}

{{PMID Auto
|PMID=21097659
|Title=Interaction effect of functional variants of the BDNF and DRD2/ANKK1 gene is associated with alexithymia in healthy human subjects.
}}

{{PMID Auto
|PMID=21162693
|Title=Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction.
|OA=1
}}

{{PMID Auto
|PMID=21172166
|Title=Pharmacogenetics of antidepressant response.
|OA=1
}}

{{PMID Auto
|PMID=21645585
|Title=Resting posterior minus frontal EEG slow oscillations is associated with extraversion and DRD2 genotype.
}}

{{PMID Auto
|PMID=21663922
|Title=Association of DRD2 and DRD3 polymorphisms with Parkinson's disease in a multiethnic consortium.
|OA=1
}}

{{PMID Auto
|PMID=21997315
|Title=ANKK1/DRD2 locus variants are associated with rimonabant efficacy in aiding smoking cessation: pilot data.
}}

{{PMID Auto
|PMID=22244514
|Title=Sensorimotor gating and D2 receptor signalling: evidence from a molecular genetic approach.
}}

{{PMID Auto
|PMID=22259185
|Title=Additive effects of serotonergic and dopaminergic polymorphisms on trait impulsivity.
}}

{{PMID Auto
|PMID=22382052
|Title=A DRD2 and ANKK1 haplotype is associated with nicotine dependence.
}}

{{PMID Auto
|PMID=22531292
|Title=Sex-specific influence of DRD2 on ADHD-type temperament in a large population-based birth cohort.
}}

{{PMID Auto
|PMID=22582185
|Title=DRD2 C957T and TaqIA Genotyping Reveals Gender Effects and Unique Low-Risk and High-Risk Genotypes in Alcohol Dependence.
}}

{{PMID Auto
|PMID=22978509
|Title=Convergence of Genome-Wide Association and Candidate Gene Studies for Alcoholism
|OA=1
}}

{{GET Evidence
|gene=ANKK1
|aa_change=Glu713Lys
|aa_change_short=E713K
|impact=pathogenic
|qualified_impact=Insufficiently evaluated pathogenic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs1800497
|overall_frequency_n=2430
|overall_frequency_d=10274
|overall_frequency=0.236519
|n_genomes=27
|n_genomes_annotated=0
|n_haplomes=35
|n_articles=18
|n_articles_annotated=17
|in_omim=Y
|in_pharmgkb=Y
|nblosum100=0
|autoscore=2
|webscore=N
}}

[[Obsessive Compulsive Disorder]]

[[Avoidance of Errors]]

[[Postoperative Nausea and Vomiting]]

{{PMID Auto
|PMID=23683269
|Title=DRD2/ANKK1 Taq1A polymorphism (rs1800497) has opposing effects on D2/3 receptor binding in healthy controls and patients with major depressive disorder
|OA=1
}}

{{PMID Auto
|PMID=23741438
|Title=Linguistic Grammar Learning and DRD2-TAQ-IA Polymorphism
|OA=1
}}

{{PMID Auto
|PMID=23840506
|Title=Multivariate analysis of dopaminergic gene variants as risk factors of heroin dependence
|OA=1
}}

{{PMID Auto
|PMID=23941313
|Title=Influence of a Dopamine Pathway Additive Genetic Efficacy Score on Smoking Cessation: Results from Two Randomized Clinical Trials of Bupropion
}}

{{PMID Auto
|PMID=24283216
|Title=Association analyses for dopamine receptor gene polymorphisms and weight status in a longitudinal analysis in obese children before and after lifestyle intervention
}}

{{PMID Auto
|PMID=24407958
|Title=Risky alcohol consumption in young people is associated with the fatty acid amide hydrolase gene polymorphism C385A and affective rating of drug pictures
}}

{{PMID|24528631}}  A variant in ANKK1 modulates acute subjective effects of cocaine: a preliminary study.

{{PMID|24512061}}  Living in the moment: Effects of time perspective and emotional valence of episodic thinking on delay discounting.

{{PMID|24379187}}  Single-nucleotide polymorphisms of the dopamine d2 receptor increase inflammation and fibrosis in human renal proximal tubule cells.

{{PMID|24001007}}  Polymorphisms in the dopamine receptor 2 gene region influence improvements during working memory training in children and adolescents.

{{PMID Auto
|PMID=22683321
|Title=Epistatic interactions implicating dopaminergic genes in bulimia nervosa (BN): relationships to eating- and personality-related psychopathology.
}}

{{PMID Auto
|PMID=22698582
|Title=DRD2/ANKK1 TaqIA and SLC6A3 VNTR polymorphisms in alcohol dependence: association and gene-gene interaction study in a population of Central Italy.
}}

{{PMID Auto
|PMID=22728571
|Title=DRD2/ANKK1 TaqI A genotype moderates the relationship between alexithymia and the relative value of alcohol among male college binge drinkers.
}}

{{PMID Auto
|PMID=22761283
|Title=Multigene interactions and the prediction of depression in the Wisconsin Longitudinal Study.
|OA=1
}}

{{PMID Auto
|PMID=22875483
|Title=Identification of a novel ANKK1 and other dopaminergic (DRD2 and DBH) gene variants in migraine susceptibility.
}}

{{PMID Auto
|PMID=22949583
|Title=Pharmacogenetic smoking cessation intervention in a health care setting: a pilot feasibility study.
|OA=1
}}

{{PMID Auto
|PMID=23118020
|Title=DRD2/ANKK1 Taq1A (rs 1800497 C>T) genotypes are associated with susceptibility to second generation antipsychotic-induced akathisia.
}}

{{PMID Auto
|PMID=23635803
|Title=ANKK1 and DRD2 pharmacogenetics of disulfiram treatment for cocaine abuse.
}}

{{PMID Auto
|PMID=23644918
|Title=Candidate glutamatergic and dopaminergic pathway gene variants do not influence Huntington's disease motor onset.
|OA=1
}}

{{PMID Auto
|PMID=24951719
|Title=Genetic Variation of the Mu Opioid Receptor (OPRM1) and Dopamine D2 Receptor (DRD2) is Related to Smoking Differences in Patients with Schizophrenia but not Bipolar Disorder
}}

{{PMID Auto
|PMID=25038551
|Title=Dopamine system genes are associated with orienting bias among healthy individuals
}}

{{PMID Auto
|PMID=25073965
|Title=Identification of ANKK1 rs1800497 variant in schizophrenia: New data and meta-analysis
}}
{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Illumina Human 1M}}